SCHEMBL6301477

SCHEMBL6301477

COc1ccc(S(=O)(=O)Nc2ccc(O)cc2)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.73
LMNA P02545 3/20 0.73
MAPK1 P28482 2/20 0.73
TUBB4A P04350 1/20 0.70
TUBB P07437 1/20 0.70
TUBA3C P0DPH7 1/20 0.70
TUBA1B P68363 1/20 0.70
TUBA4A P68366 1/20 0.70
TUBB4B P68371 1/20 0.70
TUBB3 Q13509 1/20 0.70
TUBB2A Q13885 1/20 0.70
TUBB8 Q3ZCM7 1/20 0.70
TUBA3E Q6PEY2 1/20 0.70
TUBA1A Q71U36 1/20 0.70
TUBA1C Q9BQE3 1/20 0.70
TUBB6 Q9BUF5 1/20 0.70
TUBB2B Q9BVA1 1/20 0.70
TUBB1 Q9H4B7 1/20 0.70
ALDH1A1 P00352 3/20 0.68
SMN1; SMN2 Q16637 3/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL790294 0.91 GAA (0.86) GAALMNAMAPK1ALDH1A1SMN1; SMN2
SCHEMBL19000410 0.86 PGR (0.67) GAALMNAMAPK1TUBB4ATUBB
SCHEMBL32679643 0.86 GAA (0.78) GAALMNAMAPK1ALDH1A1SMN1; SMN2
SCHEMBL1592323 0.86 UQCRB (0.76) GAALMNAMAPK1ALDH1A1SMN1; SMN2
SCHEMBL30434229 0.85 GAA (0.76) GAALMNAMAPK1ALDH1A1SMN1; SMN2
SCHEMBL7564170 0.85 GAA (0.76) GAALMNAMAPK1ALDH1A1SMN1; SMN2
SCHEMBL806437 0.85 GAA (0.76) GAALMNAMAPK1ALDH1A1SMN1; SMN2
SCHEMBL29031235 0.85 PGR (0.85) GAALMNAMAPK1ALDH1A1SMN1; SMN2
SCHEMBL8752410 0.83 GAA (0.73) GAALMNAMAPK1ALDH1A1SMN1; SMN2
SCHEMBL2240982 0.83 LMNA (0.73) GAALMNAMAPK1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119080631-A Method for preparing N-aryl amide compound by catalyzing nitrite-mediated selenium 浙江工业大学 2024-12-06 CN disclosed
EP-3334713-B1 PHENYLSULFONAMIDO-BENZOFURAN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF PROLIFERATIVE DISEASES MEMORIAL SLOAN KETTERING CANCER CENTER (US) 2021-07-21 EP disclosed
US-10975051-B2 Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases MEMORIAL SLOAN KETTERING CANCER CENTER (US) 2021-04-13 US disclosed
US-6921740-B1 Electron-receiving compound and thermal recording material MITSUBISHI PAPER MIILS LTD. (JP) 2005-07-26 US disclosed
US-6579829-B2 Aromatic sulfonamide compound MITSUI CHEMICALS, INC. (JP) 2003-06-17 US disclosed
EP-1138517-A2 Developer composition and heat sensitive recording material Mitsui Chemicals, Inc. (JP) 2001-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10975051-B2 Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases BCL2L1, BCL2, BCLAF1 GAA 2954/4885LMNA 2043/4885MAPK1 487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.